Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 0.27 · gapped above the open, then crossed back over prior close. High/low 0.28 at 8:30 am ET, 0.26 at 12:15 pm ET.
No case yet. It builds on the next filing, report or 13F period.
No peer readings for AEON Biopharma, Inc. yet.
20 managers report a position worth $9.2M between them, and 1 of them hold 80% of it.
tall tick = annual report · 1 on record
AEON Biopharma, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Manufacturing
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
AEON (AEON Biopharma, Inc.) has 2 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.